Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

Cybin Inc. N.CYBN

Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders, all protected under its ever-growing IP portfolio.

    Latest News

    Cybin to Participate in Upcoming Scientific and Investor Conferences


    Cybin Achieves Research and Development Milestones Ahead of Projected Timelines


    Cybin Announces Final Adelia Milestone Achievement


    Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment...


    Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference


    Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical...


    Cybin Announces Results of Shareholders' Meeting


    Cybin Announces Up to USD$35 Million At-The-Market Equity Program


    Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights


    Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference


    Cybin Announces Date of Annual Meeting of Shareholders


    Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003...


    Cybin Inc. (NEO:CYBN) completes acquisition of Phase 1 DMT Study from Entheon Biomedical


    Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical


    Cybin Announces Additional Adelia Milestone Achievement